Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087776 · ClinicalTrials.gov registry record · Phase 3
Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma
A Phase 3 study, sponsored by American Regent.
- Terminated
- Registry status
- Phase 3
- Development phase
- 393
- Enrollment target
NCT00087776: Clinical Trial Phase 3 study, sponsored by American Regent.
NCT00087776 is a Phase 3 study that was terminated before completion, run by American Regent. The registered enrollment target is 393 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087776, a Phase 3 study, was terminated before completion, sponsored by American Regent.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 393 participants
- Enrollment target
Study Summary
The primary objective of this trial is to compare the survival of patients with metastatic malignant melanoma treated with Taxoprexin Injection to those treated with Dacarbazine. In addition, the response rate to each drug, response duration, time to progression and time to treatment failure will be measured. Toxicity will be evaluated and compared between the two groups.
Primary Outcome
Overall survival was defined as the time from the day of randomization to participant death or the termination of the study, whichever occurs first. Participants were contacted monthly for survival information.
Interventions
- DRUG Dacarbazine
- DRUG Taxoprexin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 393 participants |
| Start Date | 2002-12-06 |
| Est. Completion | 2007-10-27 |
| Phase | Phase 3 |
Why NCT00087776 stopped before completion
NCT00087776 is an interventional study that assigns participants to a tested intervention. The registered 393 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 2 interventions - of which Dacarbazine is the first listed.
NCT00087776 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00087776 about?
NCT00087776 is a clinical study titled "Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma". The primary objective of this trial is to compare the survival of patients with metastatic malignant melanoma treated with Taxoprexin Injection to those treated with Dacarbazine. In addition, the response rate to each drug, response duration, time to progression and time to treatment failure will be...
What is the current status of trial NCT00087776?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 393 participants. The study started on 2002-12-06. Estimated completion is 2007-10-27.
What interventions are being tested in trial NCT00087776?
The interventions under investigation include: Dacarbazine (DRUG), Taxoprexin (DRUG).
Who is sponsoring clinical trial NCT00087776?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00087776's enrollment target sits among peer trials
393 967th of 2000 higher than 1,034 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05640999 · 393 participants · Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- NCT06613698 · 393 participants · Phase 2
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease
- NCT06657924 · 394 participants · Phase 2
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
- NCT07225660 · 394 participants · NA
Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI